I

Iovance Biotherapeutics
D

IOVA

5.77000
USD
0.16
(2.76%)
مغلق
حجم التداول
526,503
الربح لكل سهم
-1
العائد الربحي
-
P/E
-4
حجم السوق
1,758,585,158
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ADPT
    -0.06500
    (-0.78%)
    8.27000 USD
    A
    ALLO
    -0.07500
    (-3.33%)
    2.17500 USD
    A
    ASTS
    -2.985
    (-9.44%)
    28.620 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    F
    FATE
    -0.13500
    (-8.74%)
    1.41000 USD
    MRNA
    MRNA
    1.785
    (5.29%)
    35.535 USD
    S
    SLDB
    -0.22000
    (-3.67%)
    5.77500 USD
    المزيد
الأخبار
المقالات

العنوان: Iovance Biotherapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.